ReviewACS omega2024
Polydopamine-Modified Liposomes: Preparation and Recent Applications in the Biomedical Field.
Review in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- UCHL3 drives ferroptosis in nucleus pulposus cells by deubiquitinating HMGB1 to activate NCOA4-mediated ferritinophagy.Autophagy · 2026Article
- Construction and Characterization of PDA@MnOPharmaceutics · 2025Article
- Bioinspired Nanoplatforms: Polydopamine and Exosomes for Targeted Antimicrobial Therapy.Polymers · 2025Review
- Innovative Strategies in Oncology: Bacterial Membrane Vesicle-Based Drug Delivery Systems for Cancer Diagnosis and Therapy.Pharmaceutics · 2025Review
- Innovative Approaches to Enhancing the Biomedical Properties of Liposomes.Pharmaceutics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polydopamine (PDA) is a bioinspired polymer that has unique and desirable properties for emerging applications in the biomedical field, such as extraordinary adhesiveness, extreme ease of functionalization, great biocompatibility, large drug loading capacity, good mucopenetrability, strong photothermal capacity, and pH-responsive behavior. Liposomes are consolidated and attractive biomimetic nanocarriers widely used in the field of drug delivery for their biocompatibility and biodegradability, as well as for their ability to encapsulate hydrophobic, hydrophilic, and amphiphilic compounds, even simultaneously. In addition, liposomes can be decorated with appropriate functionalities for targeted delivery purposes. Thus, combining the interesting properties of PDA with those of liposomes allows us to obtain multifunctional nanocarriers with enhanced stability, biocompatibility, and functionality. In this review, a focus on the most recent developments of liposomes modified with PDA, either in the form of polymer layers trapping multiple vesicles or in the form of PDA-coated nanovesicles, is proposed. These innovative PDA coatings extend the application range of liposomes into the field of biomedical applications, thereby allowing for easier functionalization with targeting ligands, which endows them with active release capabilities and photothermal activity and generally improves their interaction with biological fluids. Therefore, hybrid liposome/PDA systems are proposed for surface-mediated drug delivery and for the development of nanocarriers intended for systemic and oral drug delivery, as well as for multifunctional nanocarriers for cancer therapy. The main synthetic strategies for the preparation of PDA-modified liposomes are also illustrated. Finally, future prospects for PDA-coated liposomes are discussed, including the suggestion of potential new applications, deeper evaluation of side effects, and better personalization of medical treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.